CAMBRIDGE, Mass.– ConcertAI announced Wednesday that its CancerLinQ® platform has been recognized as an ASCO Recognized Quality Solution (RQS) provider, enabling oncology practices to automate quality tracking for participation in ASCO Certified™, the American Society of Clinical Oncology’s flagship quality program.
The recognition allows CancerLinQ to submit clinical quality measures data on behalf of participating practices, eliminating manual chart abstraction that can take clinical teams 4 to 20 hours per week depending on practice size. By automating the process, oncology practices can redirect time and resources toward patient care while ensuring compliance with ASCO Certified standards.
“Oncologists knew they provided a really high level of quality care, but they didn’t have the time to manually measure it in full,” said Dr. Robert S. Miller, chief medical science officer at CancerLinQ. “We’ve given them one less thing to worry about, so they will have more time to focus on providing the best possible care to their patients.”
CancerLinQ’s automation provides comprehensive tracking across all eligible patients, rather than relying on sample audits. The platform also supports benchmarking, enabling practices to measure performance against peers and identify care gaps. The system draws on real-world data from more than 9 million patients to deliver insights, standardized quality measures, and evidence-based treatment pathways.
“This recognition is another stellar step in ConcertAI’s decade-long collaboration with ASCO and our dedication to supporting the CancerLinQ community with reliable, high-quality data solutions,” said Eron Kelly, CEO of ConcertAI. “Being an RQS provider positions us to help more practices deliver evidence-based, patient-centered care while harnessing the power of AI to drive better outcomes.”
